ReviewCurrent opinion in gastroenterology2021
New targets in inflammatory bowel disease therapy: 2021.
Review in Current opinion in gastroenterology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The efficacy of CT-P13, a biosimilar of infliximab, in inflammatory bowel diseases: a systematic review and meta-analysis.BMC gastroenterology · 2024Pooled it
- Evidence for a Modulatory Effect of a 12-Week Pomegranate Juice Intervention on the Transcriptional Response in Inflammatory Bowel Disease Patients Reducing Fecal Calprotectin Levels: Findings From a Proof-of-Principle Study.Molecular nutrition & food research · 2025Trial
- Integrated Assessment of Intestinal Barrier Function and Microscopic Inflammation Using Confocal Laser Endomicroscopy for Relapse Prediction in Ulcerative Colitis.United European gastroenterology journal · 2026Article
- Dietary polysaccharides in the management of inflammatory bowel disease: recent advances.Frontiers in nutrition · 2026Review
- T cell and cytokine signatures as early predictors of response to IL-12/IL-23 inhibition in Crohn's disease.Frontiers in immunology · 2026Article
- Disparities in Access and Treatment for Rural Patients With Inflammatory Bowel Disease: A Survey of Inflammatory Bowel Disease Patients and Providers.Inflammatory bowel diseases · 2025Article
- Gender Differences in Coping Strategies and Life Satisfaction Following Cognitive-Behavioral and Mindfulness-Based Intervention for Crohn's Disease: A Randomized Controlled Trial.Journal of clinical medicine · 2025Article
- Advancing Inflammatory Bowel Disease Treatment by Targeting the Innate Immune System and Precision Drug Delivery.International journal of molecular sciences · 2025Review
- Comparison of administration methods in adipose tissue-derived stem cell therapy in rats with colitis: An experimental study.Northern clinics of Istanbul · 2025Article
- Article
- Health-care resource use and costs associated with inflammatory bowel disease in northwest London: a retrospective linked database study.BMC gastroenterology · 2024Article
- Review
- Response to Upadacitinib in Patients with Inflammatory Bowel Disease Previously Treated with Tofacitinib.Digestive diseases and sciences · 2024Article
- Article
- Managing Ulcerative Colitis and Crohn's Disease: Should the Target Be Endoscopy, Histology, or Both?Journal of the Canadian Association of Gastroenterology · 2024Article
- Patient preferences for inflammatory bowel disease treatments: protocol development of a global preference survey using a discrete choice experiment.Frontiers in medicine · 2024Article
- Genomic insights into pediatric intestinal inflammatory and eosinophilic disorders using single-cell RNA-sequencing.Frontiers in immunology · 2024Article
- Crohn's disease and clinical management today: How it does?World journal of methodology · 2023Review
- Anti-Inflammatory Effects of Serotonin Receptor and Transient Receptor Potential Channel Ligands in Human Small Intestinal Epithelial Cells.Current issues in molecular biology · 2023Article
- Inflammatory Bowel Disease: Crosstalk between Histamine, Immunity, and Disease.International journal of molecular sciences · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
purpose of reviewIn the rapidly progressing world of inflammatory bowel disease, this review discusses and summarizes new drug targets and results from major clinical trials in order to provide an update to physicians treating patients with inflammatory bowel diseases (IBD). RECENT
findingsMultiple new mechanisms in the treatment of IBD are being developed and many are showing promising results in both ulcerative colitis and Crohn's disease patients. In addition to efficacy, some of these treatments may provide safety benefits over existing therapies. SUMMARY: The IBD physicians' therapeutic armamentarium is rapidly expanding and keeping abreast of these developments is required in order to provide patients with optimized individualized care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.